236 related articles for article (PubMed ID: 36463454)
21. Identification of BACE2 as an avid ß-amyloid-degrading protease.
Abdul-Hay SO; Sahara T; McBride M; Kang D; Leissring MA
Mol Neurodegener; 2012 Sep; 7():46. PubMed ID: 22986058
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice.
Shimshek DR; Jacobson LH; Kolly C; Zamurovic N; Balavenkatraman KK; Morawiec L; Kreutzer R; Schelle J; Jucker M; Bertschi B; Theil D; Heier A; Bigot K; Beltz K; Machauer R; Brzak I; Perrot L; Neumann U
Sci Rep; 2016 Feb; 6():21917. PubMed ID: 26912421
[TBL] [Abstract][Full Text] [Related]
23. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
[TBL] [Abstract][Full Text] [Related]
24. Association studies using novel polymorphisms in BACE1 and BACE2.
Nowotny P; Kwon JM; Chakraverty S; Nowotny V; Morris JC; Goate AM
Neuroreport; 2001 Jul; 12(9):1799-802. PubMed ID: 11435901
[TBL] [Abstract][Full Text] [Related]
25. The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease.
Shah H; Patel A; Parikh V; Nagani A; Bhimani B; Shah U; Bambharoliya T
CNS Neurol Disord Drug Targets; 2020; 19(3):184-194. PubMed ID: 32452328
[TBL] [Abstract][Full Text] [Related]
26. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer's disease.
Sadleir KR; Kandalepas PC; Buggia-Prévot V; Nicholson DA; Thinakaran G; Vassar R
Acta Neuropathol; 2016 Aug; 132(2):235-256. PubMed ID: 26993139
[TBL] [Abstract][Full Text] [Related]
27. The β-Secretase BACE1 in Alzheimer's Disease.
Hampel H; Vassar R; De Strooper B; Hardy J; Willem M; Singh N; Zhou J; Yan R; Vanmechelen E; De Vos A; Nisticò R; Corbo M; Imbimbo BP; Streffer J; Voytyuk I; Timmers M; Tahami Monfared AA; Irizarry M; Albala B; Koyama A; Watanabe N; Kimura T; Yarenis L; Lista S; Kramer L; Vergallo A
Biol Psychiatry; 2021 Apr; 89(8):745-756. PubMed ID: 32223911
[TBL] [Abstract][Full Text] [Related]
28. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells.
Rochin L; Hurbain I; Serneels L; Fort C; Watt B; Leblanc P; Marks MS; De Strooper B; Raposo G; van Niel G
Proc Natl Acad Sci U S A; 2013 Jun; 110(26):10658-63. PubMed ID: 23754390
[TBL] [Abstract][Full Text] [Related]
29. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
[TBL] [Abstract][Full Text] [Related]
30. Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor
Andrew RJ; De Rossi P; Nguyen P; Kowalski HR; Recupero AJ; Guerbette T; Krause SV; Rice RC; Laury-Kleintop L; Wagner SL; Thinakaran G
J Biol Chem; 2019 Mar; 294(12):4477-4487. PubMed ID: 30692199
[TBL] [Abstract][Full Text] [Related]
31. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
32. Cleavage of Kv2.1 by BACE1 decreases potassium current and reduces neuronal apoptosis.
Sun Q; Liu F; Zhao J; Wang P; Sun X
Neurochem Int; 2022 May; 155():105310. PubMed ID: 35231557
[TBL] [Abstract][Full Text] [Related]
33. The Structure and Function of α, β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review.
Ahmad SS; Khan S; Kamal MA; Wasi U
CNS Neurol Disord Drug Targets; 2019; 18(9):657-667. PubMed ID: 31608840
[TBL] [Abstract][Full Text] [Related]
34. BACE2 degradation is mediated by both the proteasome and lysosome pathways.
Qiu K; Liang W; Wang S; Kong T; Wang X; Li C; Wang Z; Wu Y
BMC Mol Cell Biol; 2020 Mar; 21(1):13. PubMed ID: 32160867
[TBL] [Abstract][Full Text] [Related]
35. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
36. RCAN1 Inhibits BACE2 Turnover by Attenuating Proteasome-Mediated BACE2 Degradation.
Qiu K; Wang S; Wang X; Wang F; Wu Y
Biomed Res Int; 2020; 2020():1920789. PubMed ID: 32566665
[TBL] [Abstract][Full Text] [Related]
37. The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis.
Zhao J; O'Connor T; Vassar R
J Neuroinflammation; 2011 Nov; 8():150. PubMed ID: 22047170
[TBL] [Abstract][Full Text] [Related]
38. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
[TBL] [Abstract][Full Text] [Related]
39. Berberine Alleviates Amyloid-Beta Pathology in the Brain of APP/PS1 Transgenic Mice via Inhibiting β/γ-Secretases Activity and Enhancing α-Secretases.
Cai Z; Wang C; He W; Chen Y
Curr Alzheimer Res; 2018; 15(11):1045-1052. PubMed ID: 29962345
[TBL] [Abstract][Full Text] [Related]
40. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain.
Alić I; Goh PA; Murray A; Portelius E; Gkanatsiou E; Gough G; Mok KY; Koschut D; Brunmeir R; Yeap YJ; O'Brien NL; Groet J; Shao X; Havlicek S; Dunn NR; Kvartsberg H; Brinkmalm G; Hithersay R; Startin C; Hamburg S; Phillips M; Pervushin K; Turmaine M; Wallon D; Rovelet-Lecrux A; Soininen H; Volpi E; Martin JE; Foo JN; Becker DL; Rostagno A; Ghiso J; Krsnik Ž; Šimić G; Kostović I; Mitrečić D; ; Francis PT; Blennow K; Strydom A; Hardy J; Zetterberg H; Nižetić D
Mol Psychiatry; 2021 Oct; 26(10):5766-5788. PubMed ID: 32647257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
